Log in to save to my catalogue

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with loc...

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with loc...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2506716845

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

About this item

Full title

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2021-04, Vol.22 (4), p.450-462

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundChemoradiotherapy is the standard of care for unresected locally advanced squamous cell carcinoma of the head and neck. We aimed to assess if addition of avelumab (anti-PD-L1) to chemoradiotherapy could improve treatment outcomes for this patient population. MethodsIn this randomised, double-blind, placebo-controlled, phase 3 study...

Alternative Titles

Full title

Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2506716845

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2506716845

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(20)30737-3

How to access this item